65 results on '"Frénel, J. S."'
Search Results
2. Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study
3. Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma
4. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation
5. Gynecological Carcinosarcomas
6. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
7. 21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
8. 217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort
9. 193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)
10. 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
11. 46P Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotide polymorphisms (SNPs) in ovarian cancer patients free of disease in the GINECO Vivrovaire study
12. 437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
13. 374P Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
14. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
15. 262P Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
16. 238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
17. 235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
18. 774P Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database
19. 736P Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?
20. 730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
21. 712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
22. Facteurs prédictifs de réponse au traitement
23. LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
24. 796P Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
25. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series†
26. 478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study
27. 167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
28. 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
29. 817TiP GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial
30. 803P An histopathological algorithm to help the search for POLE mutated endometrial cancers
31. 801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
32. 775P Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study
33. 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
34. 274P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
35. 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers
36. 156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
37. 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
38. 829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
39. 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
40. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
41. 343P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety preliminary results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
42. 306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
43. 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
44. 280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
45. 997PD - Validation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: An analysis from the GCIG-ENGOT-GINECO EWOC-1 study
46. 439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
47. 368P - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study
48. 307PD - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial
49. 294PD_PR - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
50. 972P - Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.